(RTTNews) - Here’s a wrap-up of some of the news that grabbed the headlines on the pharma turf in the week ended Aug.10.Barely weeks after the FDA sought more supporting data on Pristiq, a drug that Wyeth hopes to launch for the relief of menopause symptoms, the company received yet another thumbs-down vote from the FDA - this time for its investigational schizophrenia drug bifeprunox. Wyeth stock, which was trading as high as $57 at the end of June, has lost nearly 18% of it value and now, rests barely above its 52-week low of $45.44.
